Longevity Supplements [2026]: Metformin, Rapamycin — The Evidence

The longevity medicine field has moved from purely academic to commercially mainstream, with clinics offering Metformin, Rapamycin, Senolytics, and various other compounds to healthy people hoping to slow aging. The evidence base for these interventions in healthy humans varies significantly from compound to compound, and the gap between animal study promise and human evidence is consistently larger than the marketing acknowledges.

Metformin: The Most Evidence-Backed

Metformin, a diabetes medication used safely for decades, activates AMPK (an energy-sensing enzyme) and has shown life extension effects in multiple animal models. More importantly, large observational studies in humans have found that diabetic patients on Metformin outlive non-diabetic controls — a remarkable finding suggesting that the drug provides a survival benefit that exceeds what glucose control alone would produce.

The TAME (Targeting Aging with Metformin) trial — the first clinical trial specifically designed to target aging as a disease indication in humans — has been ongoing since 2021 and will be the first rigorous human evidence on Metformin as a longevity intervention. Until its results are published, Metformin for healthy people remains supported by strong observational evidence and a reasonable mechanistic basis, without the controlled trial evidence that would make it straightforwardly evidence-based.

Metformin can reduce exercise-induced adaptations — studies have found that Metformin blunts some of the mitochondrial benefits of exercise training. For people who exercise regularly, this interaction is a genuine consideration in the cost-benefit analysis.

Rapamycin: The Most Dramatic Animal Evidence

Rapamycin (an mTOR inhibitor used clinically for organ transplant rejection) has produced the most dramatic longevity effects in mouse studies of any compound tested. Administration to already-old mice extended lifespan by 14-25% in multiple studies — a larger effect than any other compound tested in the NIA Interventions Testing Program.

The human evidence for longevity effects is essentially absent — there are no randomized controlled trials of Rapamycin for longevity in healthy humans, only case reports from physicians prescribing it off-label to themselves and patients. The immunosuppressive effects (Rapamycin is used clinically at higher doses than longevity clinics prescribe because it suppresses the immune system to prevent organ rejection) create real risks that the low doses used in longevity protocols may or may not fully avoid. Infections and impaired wound healing are documented concerns even at lower doses.

Senolytics: Early Stage

Senolytics — compounds that selectively eliminate senescent cells (cells that have stopped dividing and secrete inflammatory factors) — are among the most mechanistically compelling areas in aging research. Dasatinib plus Quercetin (the most studied senolytic combination) has shown efficacy in clearing senescent cells in human trials, with early results in specific conditions (idiopathic pulmonary fibrosis, diabetic kidney disease) that are promising.

Evidence for senolytic intervention in healthy humans for general longevity purposes is preliminary — the human trials completed so far have been in specific disease populations rather than healthy aging populations. The transition from disease treatment to healthy-aging application involves a different evidence standard that hasn't been met.

Honest Bottom Line: Metformin has the strongest evidence base among longevity compounds — strong observational data in humans and the ongoing TAME trial — but interacts negatively with exercise adaptations. Rapamycin has the most dramatic animal evidence but essentially no controlled human longevity trial evidence and real immunosuppressive concerns even at low doses. Senolytics (dasatinib + quercetin) have shown disease-specific efficacy in human trials but haven't been studied in healthy aging populations. For all three compounds, the gap between animal study promise and controlled human evidence remains substantial.